

Shionogi Enters into Exclusive Licensing Agreement with OncoTherapy Science to Develop and Market Cancer Peptide Vaccines

Osaka, Japan, March 30, 2012 - Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that it has entered into a worldwide licensing agreement with OncoTherapy Science, Inc. (Head Office: Kawasaki, Kanagawa; President & CEO: Takuya Tsunoda, Ph.D.; hereafter “OTS”) to develop, manufacture and market cancer peptide vaccines.

Shionogi had previously announced a licensing agreement with OTS on February 2, 2009 for specific peptides related to five different types of oncoantigens*, discovered by OTS, which are highly expressed on cancer cells. Since that agreement became effective, Shionogi has been globally developing therapeutic vaccines incorporating these oncoantigen peptides for the treatment of patients with several types of cancers, including bladder cancer and esophageal cancer. With the completion of this new agreement, Shionogi is expanding its relationship with OTS to encompass worldwide rights to peptide vaccines discovered by OTS, for all indications. As part of this new agreement, OTS will receive an up-front payment, milestone payments at successful completion of key phases, and royalties on sales.

This expanded alliance demonstrates Shionogi’s dedication to developing innovative treatment options, as quickly as possible, for the benefit of patients worldwide.

* Oncoantigens are protein antigens that are specifically expressed in tumor cells but not in healthy cells, are critical for cancer cell growth, and are highly antigenic, effectively inducing Cytotoxic T Lymphocytes (CTL) to help target and destroy tumor cells expressing the oncoantigen without killing healthy cells.

About OncoTherapy Science, Inc.

Foundation: April 6, 2001

Chief Executive: Takuya Tsunoda, M.D., Ph.D., President and CEO

Head Office: 3-2-1 Sakado, Takatsu-ku, Kawasaki City, Kanagawa, 213-0012 Japan

Description of Business: Research on genes and gene products, and research on diseases that involve gene and gene products. Development of the treatment of the diseases and sales of the achievement brought from research and development.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications Department

Shionogi & Co., Ltd.

Telephone: +81-6-6209-7885

Fax: +81-6-6229-9596